HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers
Category: #headlines  By Saipriya Iyer  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers

 

  • HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers
  • HPV has been estimated to cause nearly 5% of cancers worldwide, majorly due to HPV serotype 16

HOOKIPA Pharma Inc.,  a developer of immunotherapeutics that target cancers and other infectious diseases based primarily on its proprietary arenavirus platform, recently announced that dosing for the first patient was completed in HB-201’s Phase 1/2 clinical trial (NCT04180215).

HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers. It will be the first clinical trial in immuno-oncology for HOOKIPA.

Apparently, HB-201 is essentially a TheraT platform-based vector that comes from the arenavirus family while expressing a highly antigenic and a non-oncogenic E6/E7 fusion protein from the HPV16. HB-201, under the preclinical studies, had been observed to be extremely immunogenic which would result in a sturdy CD8+T cell response in comparison to the levels that were induced by other approaches, which include adoptive cell therapies. 

HOOKIPA also observed a strong anti-tumor activity in the mouse models besides exhibiting a strong immunogenicity. The company firmly believes that HB-201 has the potential to help provide a therapeutic advantage to patients in the HPV16+ cancer setting.

HOOKIPA’s Chief Executive Officer, Joern Aldag stated that the company is looking forward to starting the first-in-human testing with the help of HB-201, its first clinical trial in immune-oncology. The translation of promising preclinical data for all cancer patients will be an important milestone for the company.  

Aldag further added that the approach of the company is capable of supercharging the natural defense mechanisms by having induced sturdy T cell responses for the benefit of the patients who are affected by infectious diseases and cancer.

THE HB-201 Phase 1/2 trial is basically an open-label dose-escalation as well as a dose-expansion trial to be done in 100 patients suffering from treatment-refractory HPV16+ cancers. It has been designed for the evaluation of tolerability and safety as well as preliminary efficacy of the HB-201 as a monotherapy and for combination therapy with an immune checkpoint inhibitor.

 

Source credit- https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-announces-first-patient-dosed-phase-12-clinical-trial-hb

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

Patanjali plans to sell food retail biz to Ruchi Soya for $88Mn
Patanjali plans to sell food retail biz to Ruchi Soya for $88Mn
By Saipriya Iyer

Indian multinational conglomerate holding company, Patanjali Ayurved has recently signed an agreement to sell its food retail unit to Ruchi Soya Industries for Rs 690 crore (USD 88 Million). The deal, which comprises 21 major products such as hone...

Apollo in talks to pump $1Bn into India’s residential property market
Apollo in talks to pump $1Bn into India’s residential property market
By Saipriya Iyer

Apollo Global Management Inc., an American investment management firm, is reportedly planning to lend around $1 billion to Indian property developers this year, making a bet on the recovery of the country’s residential property market as the CO...

Meta platforms join hands with AMD to make broadband more accessible
Meta platforms join hands with AMD to make broadband more accessible
By Saipriya Iyer

The two companies will collectively work on mobile internet infrastructure program This partnership aims to reduce base station cost and make broadband more accessible   Meta Platforms Inc., the parent company of Facebook, has rece...